We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Tapestry Presents Data Supporting the Oral Bioavailability and Antitumor Activity of TPI 287
News

Tapestry Presents Data Supporting the Oral Bioavailability and Antitumor Activity of TPI 287

Tapestry Presents Data Supporting the Oral Bioavailability and Antitumor Activity of TPI 287
News

Tapestry Presents Data Supporting the Oral Bioavailability and Antitumor Activity of TPI 287

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Tapestry Presents Data Supporting the Oral Bioavailability and Antitumor Activity of TPI 287"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Tapestry Pharmaceuticals, Inc. has presented data on its lead oncology drug candidate TPI 287 at the 97th Annual Meeting of the American Association for Cancer Research (AACR) in Washington, DC.

Data presented indicates that TPI 287 is orally bioavailable in rats and that oral dosing of TPI 287 has antitumor activity in a mouse xenograft model.

In addition, data were presented from in vitro transport assays which demonstrate that TPI 287 is not a substrate for drug efflux in the MDCKII-MDR monolayer system and that TPI 287 demonstrates increased potency in cell cytotoxicity assays with MDR 1+ and mutant tubulin expressing tumor cell lines when compared to paclitaxel. 

A poster entitled "Oral Bioavailability and antitumor activity of TPI 287 - a new taxane analog with greater activity against tumor cells with demonstrated mutant tubulin," Abstract No. 493, by David L. Emerson, Carol Bell, Mark Jones, Barbara Schiemann and Gilles Tapolsky was presented Sunday, April 2, 2006 at 8:00 AM.

Advertisement